Results suggest that even in endemic settings, highly virulent clones can rapidly emerge demanding constant monitoring.
Scientists have genetically manipulated a harmless form of E. coli to create a vaccine that protects against a hypervirulent form of Klebsiella pneumoniae in mice.
Epidemiologic data and whole genome sequencing revealed a transmission of more than three years duration of New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae with antibiotic-resistant genes in a northern California hospital.
Scientists were able to determine that the strain that had sickened the patient had been in circulation in the hospital for at least a year prior to the patient's death, spreading between patients and throughout the wards of the hospital. It even traveled among the three campuses of the hospital, which were miles apart. The analysis also found that the isolates of the highly drug-resistant outbreak strain were carrying multiple antibiotic resistance genes and plasmids.
Researchers at an Indian hospital have identified strains of hypervirulent, carbapenem-resistant Klebsiella pneumoniae associated with extremely high mortality rates. The findings represent the first report of a hypervirulent form of the drug-resistant pathogen in India.
A virulent strain of Klebsiella pneumoniae that is resistant to carbapenem and colistin has been isolated for the first time from a patient in the US.
Researchers report the genomic characterization of an unusual Klebsiella pneumoniae, nonsusceptible to all 26 antibiotics tested, that was isolated from a US patient.
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics.
Researchers have detected heteroresistance to colistin in already highly resistant Klebsiella pneumoniae.
Researchers found that interferons are fighting back against the bacterial Klebsiella infection.